ELX1 007

Drug Profile

ELX1 007

Alternative Names: ELX1-007; ELX1.007; FirstCover

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elanix Biotechnologies
  • Developer Elanix Biotechnologies; University Hospital of Lausanne
  • Class Biological factors; Cytokines; Growth factors; Skin disorder therapies; Tissue extracts
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Wounds

Most Recent Events

  • 06 Sep 2016 Clinical trials in Wounds in Switzerland (Topical)
  • 06 Sep 2016 ELX1 007 receives Advanced Therapeutic Medicinal Product designation in Europe before September 2016 (Elanix Biotechnologies pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top